Status:
COMPLETED
Nutrigenomics: Personalizing Weight Loss for Obese Veterans
Lead Sponsor:
University of California, San Diego
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to determine if providing genomic information to veterans can help them lose weight compared to usual care.
Detailed Description
About 35% of veterans are obese. The MOVE! program is a nation-wide 8-week program of group classes nationally to help obese veterans lose weight. While the program is successful for some veterans, ab...
Eligibility Criteria
Inclusion
- Veterans able to receive care at the VASDHS and planning to start the MOVE! program.
- Veterans able to understand and consent to the study.
- BMI equal to or greater than 30 kg/m2.
Exclusion
- Veterans unable to receive care at the VASDHS.
- Veterans unable to understand the consent process at the discretion of the PI.
- Active substance abuse or substance dependence disorder
- Cognitive disorder, psychiatric hospitalization in past 6-months, or presence of suicidal ideation identified on self-report instruments
- Bradycardia, rapid heart rate or other arrhythmia or active ischemia by EKG.
- Uncontrolled thyroid disease as measured by a TSH above or below the normal range.
- Body mass index \< 30 kg/m2.
- Chronic kidney disease stage III or higher by National Kidney Foundation criteria (GFR = 30-59 ml/min).
- New York Heart Association's functional classification of congestive heart failure above Class I (not limited with normal physical activity by symptoms; Class II occurs when ordinary physical activity results in fatigue, dyspnea, or other symptoms).
- Sodium or potassium outside the normal range.
- Edema requiring the use of daily diuresis with furosemide, bumex or other diuretic (does not include hydrochlorthiazide).
- The use of high dose oral corticosteroids (above replacement doses).
- Veterans deficient in 25-OH vitamin D (\<20 units/dl).
- Veterans with fasting LDL \> 190 mg/dl.
- Veterans with fasting triglyceride levels \> 1000 mg/dl.
- Excessive caffeine use (\>6 caffeinated beverages/days).
- Prior gastrointestinal surgery with the exception of distal appendectomy.
- Acute infections or current use of antibiotic therapy.
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01859403
Start Date
November 1 2012
End Date
March 1 2014
Last Update
April 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA San Diego Healthcare System
San Diego, California, United States, 92161